Fig. 4From: Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)Landscape of HER2 signaling pathways and mechanistic basis for angiogenesis inhibitor and HER2-targeted agents in HER2-altered NSCLCBack to article page